Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease

被引:67
|
作者
Du, Xi-Xun [1 ]
Xu, Hua-Min [1 ]
Jiang, Hong [1 ]
Song, Ning [1 ]
Wang, Jun [1 ]
Xie, Jun-Xia [1 ]
机构
[1] Qingdao Univ, Coll Med, Dept Physiol, Shandong Prov Key Lab Pathogenesis & Prevent Neur, Qingdao 266071, Peoples R China
基金
中国国家自然科学基金;
关键词
6-hydroxydopamine; curcumin; Parkinson's disease; dopaminergic neurons; iron; METAL TRANSPORTER 1; SUBSTANTIA-NIGRA; ANIMAL-MODELS; ANTIOXIDANT; CELLS; DEGENERATION; FLAVONOIDS; CADMIUM; BRAIN; MPTP;
D O I
10.1007/s12264-012-1238-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Curcumin is a plant polyphenolic compound and a major component of spice turmeric (Curcuma longa). It has been reported to possess free radical-scavenging, iron-chelating, and anti-inflammatory properties in different tissues. Our previous study showed that curcumin protects MES23.5 dopaminergic cells from 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in vitro. The present study aimed to explore this neuroprotective effect in the 6-OHDAlesioned rat model of Parkinson's disease in vivo. Rats were given intragastric curcumin for 24 days. 6-OHDA lesioning was conducted on day 4 of curcumin treatment. Dopamine content was assessed by high-performance liquid chromatography with electrochemical detection, tyrosine hydroxylase (TH)-containing neurons by immunohistochemistry, and iron-containing cells by Perls' iron staining. The dopamine content in the striatum and the number of TH-immunoreactive neurons decreased after 6-OHDA treatment. Curcumin pretreatment reversed these changes. Further studies demonstrated that 6-OHDA treatment increased the number of iron-staining cells, which was dramatically decreased by curcumin pretreatment. The protective effects of curcumin against 6-OHDA may be attributable to the ironchelating activity of curcumin to suppress the iron-induced degeneration of nigral dopaminergic neurons.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 50 条
  • [31] Respiratory activity in the 6-hydroxydopamine model of Parkinson's disease in the rat
    Budzinska, Krystyna
    Andrzejewski, Kryspin
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2014, 74 (01) : 67 - 81
  • [32] Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson's Disease
    Pislar, Anja
    Tratnjek, Larisa
    Glavan, Gordana
    Zivin, Marko
    Kos, Janko
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2018, 11
  • [33] Characterising a New Sheep Model of Parkinson's Disease Using Unilateral Intracerebral Injection of 6-Hydroxydopamine Into the Substantia Nigra
    Banstola, Ashik
    Vautrelle, Nicolas
    Bergin, David
    Mohammad, Younus
    Gandhi, Kushan
    Rizwan, Shakila
    Reynolds, John N. J.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2025, 61 (02)
  • [34] Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease
    Shim, Jin Sup
    Kim, Hyo Geun
    Ju, Mi Sun
    Choi, Jin Gyu
    Jeong, Seo Young
    Oh, Myung Sook
    JOURNAL OF ETHNOPHARMACOLOGY, 2009, 126 (02) : 361 - 365
  • [35] Intake of Tomato-Enriched Diet Protects from 6-Hydroxydopamine-Induced Degeneration of Rat Nigral Dopaminergic Neurons
    di Matteo, Vincenzo
    Pierucci, Massimo
    Di Giovanni, Giuseppe
    Dragani, Luana Katia
    Murzilli, Stefania
    Poggi, Andreina
    Esposito, Ennio
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2009, (73): : 333 - 341
  • [36] Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease
    Quintero, Elias Matthew
    Willis, Lauren
    Singleton, Rachel
    Harris, Naida
    Huang, Peng
    Bhat, Narayan
    Granholm, Ann-Charlotte
    BRAIN RESEARCH, 2006, 1093 : 198 - 207
  • [37] Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson’s Disease
    Sang J. Na
    Anthony G. DiLella
    Edward V. Lis
    Keith Jones
    David M. Levine
    David J. Stone
    J. F. Hess
    Neurochemical Research, 2010, 35 : 761 - 772
  • [38] Acetyl-L-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat
    Afshin-Majd, Siamak
    Bashiri, Keyhan
    Kiasalari, Zahra
    Baluchnejadmojarad, Tourandokht
    Sedaghat, Reza
    Roghani, Mehrdad
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 89 : 1 - 9
  • [39] Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease
    Sadeghian, M.
    Mullali, G.
    Pocock, J. M.
    Piers, T.
    Roach, A.
    Smith, K. J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (05) : 423 - 435
  • [40] The footfault test as a screening tool in the 6-hydroxydopamine rat model of Parkinson's disease
    Silvestrin, Roberta Bristot
    de Oliveira, Lucas Fuerstenau
    Batassini, Cristiane
    Oliveira, Alcyr
    Mello e Souza, Tadeu
    JOURNAL OF NEUROSCIENCE METHODS, 2009, 177 (02) : 317 - 321